Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Immunovia Half-year report 2016

“Immunovia reached several important milestones in the first six months of 2016. Good results were obtained in the American pancreas study that was carried out in collabo­ration with Knight Cancer Institute. Presentations made at the key global conferences concerning pancreatic cancer were very well received. A specially strong Scientific Advisory Board has been recruited, and involvement from the patient organization has increased. Furthermore, several significant agreements were signed with important cancer centres. The market introduction of IMMray™ PanCan –d, Immunovia’s diagnosis

Nanologica enters into research collaboration with GSK

Nanologica has signed a Services Agreement with GSK to apply its expertise in nanoporous materials and customized drug delivery systems to advance the development of new technology platforms for early stage development projects.”We are excited about the collaboration with GSK. This is an early, but interesting project with the possibility to unlock new approaches to personalized medicine. It is a great opportunity for Nanologica to contribute to this field,” says Nanologica’s CEO Andreas Bhagwani. This paid development project is in line with Nanologica’s strategy in the business area

NeuroVive’s Chief Operating Officer Jan Nilsson leaves the company

Lund, Sweden, August 24, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that its Chief Operating Officer, Jan Nilsson leaves the company.The company is entering into a very important period and is expecting exciting developments during the fall. Over the past several months, the business strategy and organization have been re-oriented to optimize the way forward. As one consequence the position of COO is no longer required. “I have been involved in NeuroVive in different roles since 2010 and it has been

Cantargia interim report January – June 2016

Cantargia AB (“Cantargia”) interim report for January – June 2016 is available on the company website (www.cantargia.com/Investors/Reports).Significant events in the second quarter  · The exercise period for warrants of series TO 1 and TO 3 began on 23 March 2016 and ended on 13 April 2016. In total, 4,127,260 warrants of both series were exercised, representing around 83.5 per cent of the number of warrants issued. Through the warrants Cantargia raised approximately SEK 31.4 million before issue costs.  · During the period the Company gave investor presentations at the

ÅF wins major order from Chr. Hansen in Denmark

For further information:Per Magnusson, President Industry Division +46 70 676 64 26, per.magnusson@afconsult.com.Magnus Andrén, Area Sales Manager Food and Pharma, +46 10 505 52 71, magnus.andren@afconsult.com. ÅF has signed a new contract with the bioscience company Chr. Hansen A/S, worth about EUR 5.5 million. ÅF will modernize Chr. Hansen`s production plant in Roskilde, Denmark and the order is an end-to-end solution. The plant in Roskilde produces probiotics used in food and pharmaceutical industries.  "With a new modern production plant we will meet the higher capacity

Konecranes provides further financial information on Stahl CraneSystems

On August 8, 2016, Konecranes announced that it has received approval from the European Commission for its pending acquisition of Terex’s MHPS business (“MHPS Acquisition”). The approval is conditional on a commitment by Konecranes to divest its STAHL CraneSystems business. Furthermore, Konecranes stated that STAHL CraneSystems’ external sales totaled EUR 145 million in 2015 and the company has approximately 700 employees. To facilitate the divestment process, Konecranes announces that STAHL CraneSystems’ pro forma EBITDA on a stand-alone basis would have totaled approximately EUR 30

C-RAD AB - Interim report April-June 2016

Key events in the period April-June 2016   · Net sales: Apr-Jun 15.6 (15.1) MSEK, +3% · Rolling 12m 68.4 (59.4) MSEK +15% · Order intake: Apr-Jun 30.4 (16.3) MSEK, +87% · Rolling 12m 93.1 (81.2) MSEK +15% · Operating loss: Apr-Jun -9.8 (-5.4) MSEK · Net results per share: Apr-Jun -0.44 (-0.28) · Rights issue provides C-RAD with 45.4 MSEK before issue costs · Leading cancer centers in China to be equipped with C-RAD technology   Comments from Tim Thurn, CEO:   Second quarter: Highest quarterly order intake in C-RADs history   The second quarter

WntResearch announces organizational changes

WntResearch today announces that the company reinforces its organization by the recruitment of Dennis Henriksen to the newly established position as Chief Technical Officer. Furthermore, a recruitment process has commenced to find a successor for WntResearch’s Chief Medical Officer Nils Brünner who is leaving his position at the end of the year, and is instead expected to become elected as member of the Board of Directors.By the instalment of the position as Chief Technical Officer and by the recruitment of Dennis Henriksen, the company strengthens its in-house competence and resources

Final closure of the restructuring of Agasti

In the second quarter of 2016, the Agasti Group (in liquidation) (in the following sections "Agasti" is used), had a net income of NOK -187 million, bringing net income for the first half of the year to NOK -182 million. The corresponding figures for 2015 were NOK 8 million and NOK 25 million, respectively. The financial results are affected by a loss of NOK 199 million following the sale of Agasti's 66 per cent share in Obligo Holding AS and other assets to Audrey Management Holdings S.á.r.l., a company controlled by Blackstone L.P (Blackstone Real Estate Funds), which already owned the

Interim Report Second Quarter 2016

Second quarter · Net sales increased by 8% to SEK 115.6 (107.0) million. Adjusted to fixed exchange rates, net sales increased by 12%. · Operating profit, excluding non-recurring items, increased by 8% to SEK 42.7 (39.5) million. · Profit before tax, excluding non-recurring items, increased by 12% to SEK 33.5 (30.0) million. · Diamorph AB (publ) acquired a further 10% of Diamorph Bearings AB from 2 of the minority shareholders for consideration of SEK 22.8 million. First half   · Net sales were flat at SEK 223.0 (223.9) million. Adjusted to fixed exchange rates, net

Elos Medtech Interim report, 1 January – 30 June 2016

Sales growth and improved operating profit• Net sales for the first half of the year increased to SEK 292.0 M (244.6), which adjusted for exchange-rate fluctuations corresponds to an increase of 20.2%, of which organic growth was 1.1%. • Operating profit totalled SEK 28.0 M (19.4, adjusted for non-recurring items of 26.4). • Profit after net financial items totalled SEK 21.3 M (16.7). Net financial items were negatively impacted by exchange-rate differences of SEK 0.2 M (pos: 0.3).  • Profit after tax amounted to SEK 15.1 M (11.3), corresponding to SEK 2.49 (1.87) per share. •

David Nuutinen steps down as CEO – search for new CEO initiated

David Nuutinen, President and CEO of Cloetta, has due to private reasons decided to leave Cloetta as of 1 September. Danko Maras, CFO, will assume the position as interim President and CEO. The Board of Directors will immediately initiate a process to find a permanent CEO.“David Nuutinen has been a successful and appreciated leader in Cloetta during his thirteen years with the company, including the last year as CEO. Therefore, I very much regret that he has decided to leave Cloetta and on behalf of the Board I would like to express our sincere thanks and appreciation to David for his

AZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER

This announcement contains inside information 24 August 2016 07:00 ASTRAZENECA TO SELL SMALL MOLECULE ANTIBIOTICS BUSINESS TO PFIZER Value-creating divestment supports AstraZeneca’s focus on three main therapy areas Pfizer’s dedicated focus on infectious diseases willextend the reach of the antibiotics to more patients globally and maximise the potential of the late-stage, small molecule antibiotics business AstraZeneca today announced that it has entered into an agreement with Pfizer Inc. (Pfizer) to sell the commercialisation and development rights to its late-stage

Systemair receives major order for Cruise Line Ships from MAC Hamburg

Systemair ABs (NASDAQ OMX Stockholm: SYSR) company in the Netherlands has received an order for production of air handling units, of a value of approx. EUR 6 million, from MAC Hamburg for two new ships. The new cruise line ships will be built at Meyer Yard in Papenburg Germany and will be 165.000 tons ships for 4.200 passengers each. The air handling units will be delivered during 2017 and 2018. Systemair in the Netherlands will deliver 88 air handling units made of stainless steel for each ship. "We are proud to be selected to deliver the air handling units for these prestigious

SinterCast Results April-June 2016

Series production at record level, installation outlook positive Second Quarter 2016 · Revenue for Period: SEK 18.3 million (SEK 15.8 million) · Operating Result: SEK 5.8 million (SEK 2.9 million) · Earnings per Share: SEK 0.8 per share (SEK 0.5 per share) · Cashflow from Operations: SEK 4.4 million (SEK 4.8 million) · Series production equals record high of 2.2 million Engine Equivalents · US Automotive Science GroupTM awards Ford F-150 with CGI engine "Best Environmental Performance" · Ladle TrackerTM technology launched; first installation in operation ·

Lundbeck increased revenue by 5% driven by US sales growth of 33% leading to improved profitability and increased financial guidance for 2016

HIGHLIGHTS· Revenue reached DKK 7,521 million in the first half of 2016 representing an increase of 5% in both reported and local currencies compared to the same period last year · Total revenue has delivered a better performance than expected driven by Xenazine® and key products · US revenue increased 33% (31% in local currency) to DKK 3,840 million · Revenue in International Markets declined 5% (unchanged in local currencies) to DKK 2,033 million · Europe declined 26% (25% in local currencies) to DKK 1,453 million · Revenue from key products grew 99% (99% in local

Konecranes Plc’s Nomination and Compensation Committee's proposal for new members of the Board of Directors

As announced in notice to the Extraordinary General Meeting of Konecranes Plc on July 15, 2016, the Nomination and Compensation Committee of the Board of Directors proposes to the General Meeting to be held on September 15, 2016, that two new members of the Board of Directors be elected for a term of office ending at the closing of the Annual General Meeting in 2017. The Committee proposes that Ms. Janina Kugel and Mr. Ulf Liljedahl be elected as new members of the Board. M.Sc. (Econ.) Janina Kugel, b. 1970, has been Chief Human Resources Officer and Member of the Managing Board of

Ulf Larsson appointed Executive Vice President of SCA

Effective immediately, SCA’s Board of Directors has appointed Ulf Larsson, current President of SCA Forest Products and a member of the Executive Management Team, Executive Vice President of SCA. This is in addition to his current assignments.Ulf Larsson started at SCA in 1992. Ulf has a BSc Forestry, Swedish University of Agricultural Sciences, Umeå, Sweden. He has held several leading positions within SCA Forest Products. NB: This information is information that SCA is obliged to make public pursuant to the EU Market Abuse Regulation or the Securities Markets Act. The information was

SCA plans to split the Group into two listed companies in 2017, hygiene and forest products

SCA is a leading global hygiene and forest products company. Today about 85% of the Group sales derives from the hygiene business and about 15% from the forest products business. To create further value for the shareholders, the SCA Board of Directors plans to initiate work in order to propose to the Annual General Meeting 2017 to decide on a split of the Group into two listed companies. This is planned to be completed through a distribution of the Group’s hygiene business to its shareholders in accordance with the rules of Lex Asea*. In the event of a distribution of the hygiene business,

Second quarter report 2016

24 August 2016 · Net sales increased by 12 percent to MSEK 1,503.5 (1,341.3), and by 15 percent at constant exchange rates. The increase refers mainly to Norway and Sweden. Net sales for comparable units, i.e. excluding Finland and Sødams in Denmark, increased by 12 percent at constant exchange rates. · Adjusted operating income* declined by 4 percent to MSEK 74.3 (77.0), corresponding to a margin of 4.9 (5.7) percent. Adjusted operating income increased in Norway and Sweden, but declined in Denmark. Adjusted operating income for comparable units increased by 11 percent. · Income

ÅF wins major order from Chr. Hansen in Denmark

ÅF has signed a new contract with the bioscience company Chr. Hansen A/S, worth about EUR 5.5 million. ÅF will modernize Chr. Hansen`s production plant in Roskilde, Denmark and the order is an end-to-end solution. The plant in Roskilde produces probiotics used in food and pharmaceutical industries. “With a new modern production plant we will meet the higher capacity demands from our customers. ÅF’s competence and experience from similar projects made them the best partner to us”, says Esben Terstrup, Director, Human Health Production at Chr. Hansen. The contract covers installation of

Höegh LNG - Webcast details for the second quarter of 2016 results

Höegh LNG Holdings Ltd. ("Höegh LNG" or the "Group") will release its results for the second quarter of 2016 on Thursday 25 August 2016 at 07:00 am CET. In connection with this, the Group will hold a webcast at 09:00 am CET. The webcast is accessible via a link on Höegh LNG's website at http://webtv.hegnar.no/presentation.php?webcastId=36207892. The webcast will immediately be followed by a Q&A session that participants can join by using the following dial-in numbers: Norway +47 23 50 01 87United Kingdon +44 (0)20 3364 5726United States +1 719-325-2238Participant passcode:

Invitation to Clas Ohlson’s Q1 presentation on 7 September

On 7 September 2016 at 07:00 CET Clas Ohlson will publish its three-month report 2016/17. A presentation of the report will be held the same day at 08:30 at the store on Drottninggatan in Stockholm, Sweden.Clas Ohlson invites investors, asset managers, financial analysts and the media to a presentation where CEO Klas Balkow will comment on the report. The presentation will be held at 08:30 CET in Clas Ohlson’s store at Drottninggatan 53 in Stockholm, Sweden. The presentation will be held in English. The report will be published at 07:00 CET and available for download at http://about.

NORDIC NANOVECTOR ASA – RESULTS FOR SECOND QUARTER AND HALF YEAR 2016

BETALUTIN® DEVELOPMENT AND ALL OPERATIONS ADVANCING ACCORDING TO SCHEDULE; PROMISING CLINICAL RESULTS REPORTED AT AMERICAN ASSOCIATION OF CANCER (AACR)Oslo, Norway, 24 August 2016 Nordic Nanovector ASA (OSE: NANO) announces its results for second quarter and half year 2016. A presentation of the results by the company’s senior management team will take place today at 8:30 a.m. CEST in Oslo - details below. Nordic Nanovector has continued to make good progress in executing its clinical development plan for Betalutin®. Patient recruitment is on track and all study sites have been

There are no items matching the current filter
There are no more items matching the current filter
Back to top